HeartBeam's Stock Rises on FDA Clearance and Upgraded Analyst Ratings

HeartBeam (BEAT) shares are trading higher after Benchmark upgraded its rating to Buy with a price target of $8.00, alongside FDA granting 510(k) clearance for the company's ECG software.